Literature DB >> 32201314

Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges.

Ming Li1, Qian Wang1, Yong Li1, Shengtian Cao1, Yingjun Zhang2, Zhongqing Wang2, Guozhu Liu2, Jing Li3, Baohua Gu4.   

Abstract

Apical Sodium-dependent Bile Acid Transporter (ASBT) actively reabsorbs bile acids (BAs) from the gut lumen. This process is a critical step in the enterohepatic circulation (EHC) of BAs and plays important roles in the homeostasis of BAs in the body. Therefore, ASBT is considered a favorite target for intervention to regulate the levels of BAs, cholesterol, lipid and glucose etc. In addition, ASBT is also a popular delivery target for developing prodrugs, due to its intestinal localization, high expression and high uptake capacity. In the past ten years, ASBT has been the focus by both academia and pharmaceutical industry as research targets not only for BA-related diseases but also for prodrug delivery. Numerous studies have been published and many candidate ASBT inhibitors are being developed. Here we review and summarize the current states of ASBT research with a focus on the therapeutic applications of ASBT as a target for therapy as well as a delivery target for prodrugs. The current and future challenges in ASBT research and outlook of drug developments are discussed.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  ASBT inhibitor; ASBT prodrug; Apical sodium-dependent bile acid transporter; Delivery target; Drug target; Drug-drug interaction

Mesh:

Substances:

Year:  2020        PMID: 32201314     DOI: 10.1016/j.pharmthera.2020.107539

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  9 in total

1.  Structure of the bile acid transporter and HBV receptor NTCP.

Authors:  Jinta Asami; Kanako Terakado Kimura; Yoko Fujita-Fujiharu; Hanako Ishida; Zhikuan Zhang; Yayoi Nomura; Kehong Liu; Tomoko Uemura; Yumi Sato; Masatsugu Ono; Masaki Yamamoto; Takeshi Noda; Hideki Shigematsu; David Drew; So Iwata; Toshiyuki Shimizu; Norimichi Nomura; Umeharu Ohto
Journal:  Nature       Date:  2022-05-17       Impact factor: 49.962

2.  Biomimetic and temporal-controlled nanocarriers with ileum transporter targeting for achieving oral administration of chemotherapeutic drugs.

Authors:  Wei Liu; Ying Han; Xin Xin; Liqing Chen; Yanhong Liu; Chao Liu; Xintong Zhang; Mingji Jin; Jingzhe Jin; Zhonggao Gao; Wei Huang
Journal:  J Nanobiotechnology       Date:  2022-06-15       Impact factor: 9.429

Review 3.  Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis.

Authors:  Takeshi Katafuchi; Makoto Makishima
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

Review 4.  Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.

Authors:  Baoyi Guan; Jinlin Tong; Haiping Hao; Zhixu Yang; Keji Chen; Hao Xu; Anlu Wang
Journal:  Acta Pharm Sin B       Date:  2021-12-22       Impact factor: 14.903

Review 5.  Bile Acids Transporters of Enterohepatic Circulation for Targeted Drug Delivery.

Authors:  Robin Durník; Lenka Šindlerová; Pavel Babica; Ondřej Jurček
Journal:  Molecules       Date:  2022-05-05       Impact factor: 4.927

6.  Total flavonoids of Astragalus Ameliorated Bile Acid Metabolism Dysfunction in Diabetes Mellitus.

Authors:  Zhe Wang; Xu-Ling Li; Kin-Fong Hong; Ting-Ting Zhao; Rui-Xue Dong; Wei-Ming Wang; Yun-Tong Li; Gui-Lin Zhang; Jing Lin; Ding-Kun Gui; You-Hua Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-12       Impact factor: 2.629

Review 7.  Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.

Authors:  Boyan Zhang; Folkert Kuipers; Jan Freark de Boer; Jan Albert Kuivenhoven
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

8.  L-Arabinose improves hypercholesterolemia via regulating bile acid metabolism in high-fat-high-sucrose diet-fed mice.

Authors:  Yu Wang; Jiajia Zhao; Qiang Li; Jinxin Liu; Yujie Sun; Kuiliang Zhang; Mingcong Fan; Haifeng Qian; Yan Li; Li Wang
Journal:  Nutr Metab (Lond)       Date:  2022-04-15       Impact factor: 4.654

9.  MiR-203 is an anti-obese microRNA by targeting apical sodium-dependent bile acid transporter.

Authors:  Xin Liu; Feiran Cheng; Xue Bai; Tong Zhao; Limin Zhao; Lei Wang; Mingqi Li; Xianxian Wu; Xiaohui Chen; Pingping Tang; Mengxue Wang; Lintong Jiang; Chaoqi Yan; Fenghua Pei; Xu Gao; Ning Ma; Baofeng Yang; Yong Zhang
Journal:  iScience       Date:  2022-07-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.